Zydus Lifesciences bags USFDA approval for Carbidopa and Levodopa Tablets to treat Parkinson's disease symptoms

The product will be manufactured at the group's formulation manufacturing facility in SEZ Ahmedabad, India.

Published On 2023-04-06 09:02 GMT   |   Update On 2023-04-06 09:02 GMT

Ahmedabad: Zydus Lifesciences Limited today announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg (USRLD: Sinemet Tablets, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg).Carbidopa and Levodopa is used to treat symptoms...

Login or Register to read the full article

Ahmedabad: Zydus Lifesciences Limited today  announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg (USRLD: Sinemet Tablets, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg).

Carbidopa and Levodopa is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). This medicine is also used to treat Parkinson symptoms caused by carbon monoxide, carbon monoxide poisoning or manganese intoxication.

The product will be manufactured at the group’s formulation manufacturing facility in SEZ Ahmedabad, (India).

Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg had annual sales of USD 75 mn in the United States (IQVIA MAT Dec. 2022). The group now has 359 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Read also: Zydus Lifesciences bags USFDA nod for Levothyroxine Sodium for Injection for myxedema coma treatment

Medical Dialogues team had earlier reported that the company's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. had received tentative approval from the USFDA to market Amantadine Extended-Release Capsules USP 68.5 mg and 137 mg (USRLD: Gocovri). The product is  indicated for the treatment of dyskinesia (sudden uncontrolled movements) in patients with Parkinson's disease who are treated with levodopa therapy, with or without dopaminergic medicines.

Read also: Zydus Amantadine ER Capsules gets USFDA okay

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), an Indian Pharmaceutical company is a fully integrated, global healthcare provider. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News